← Leaderboards
Rebecca Marie Zash
Beth Israel Deaconess Medical Center
$3,541,756
Attributed
$3,790,270
Total exposure
3
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.1M · FY2017–25$2M$1.5M$1M$500K$0
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$3,790,270 · 3
By mechanism
R01$2,970,665 · 2
K23$819,605 · 1
Top collaborators
- Roger L Shapiro1 shared
Most similar at Beth Israel Deaconess Medical Center
Same institution · by research overlap
- Marlene Beth Goldman$3,229,477
- Michele Renee Hacker$1,926,199
- Christopher A Walsh$66,138,888
Others in their field
Other Emerging Leaders on “Pregnancy”
- Chanza Baytop · Westat, Inc.$271,217,917
- Jorge Eduardo Chavarro · Harvard School Of Public Health$13,845,291
- Tomasz Nowakowski · University Of California, San Francisco$13,203,364
- Barney Sparrow · Battelle Memorial Institu$13,048,137
- Magdalena Zernicka-Goetz · California Institute Of Technology$11,182,591
- Sara Bonamo Demauro · Children'S Hosp Of Philadelphia$11,044,839
Research focus
PregnancySitePharmaceutical PreparationsWomanEnrollmentLinkBotswanaHiv InfectionsPediatric Human Immunodeficiency Virus InfectionHigh RiskEpidemiologySuccessProgramsReproductiveInfrastructureChildhoodSafetyCountryPre-Exposure ProphylaxisMothersMaternal WeightHigh Risk WomanEvaluationGuidelines
Grant awards (11)
Tsepamo Next Generation: Optimizing HIV Treatment and Prevention Strategies for Pregnant Women in Botswana$497,029
R01 · FY2025 · HD
Linking HIV Prevention and post-partum care: Safety, efficacy and feasibility of cabotegravir-LA PrEP in high-risk breastfeeding population in Botswana$388,881
R01 · FY2025 · HD · contact PI
Linking HIV Prevention and post-partum care: Safety, efficacy and feasibility of cabotegravir-LA PrEP in high-risk breastfeeding population in Botswana$221,794
R01 · FY2025 · HD · contact PI
Linking HIV Prevention and post-partum care: Safety, efficacy and feasibility of cabotegravir-LA PrEP in high-risk breastfeeding population in Botswana$586,400
R01 · FY2023 · HD · contact PI
Linking HIV Prevention and post-partum care: Safety, efficacy and feasibility of cabotegravir-LA PrEP in high-risk breastfeeding population in Botswana$608,435
R01 · FY2022 · HD · contact PI
Linking HIV Prevention and post-partum care: Safety, efficacy and feasibility of cabotegravir-LA PrEP in high-risk breastfeeding population in Botswana$668,126
R01 · FY2021 · HD · contact PI
Decreasing Adverse Birth Outcomes among HIV-infected Women on Antiretroviral Therapy$164,376
K23 · FY2021 · HD · contact PI
Decreasing Adverse Birth Outcomes among HIV-infected Women on Antiretroviral Therapy$164,376
K23 · FY2020 · HD · contact PI
Decreasing Adverse Birth Outcomes among HIV-infected Women on Antiretroviral Therapy$164,376
K23 · FY2019 · HD · contact PI
Decreasing Adverse Birth Outcomes among HIV-infected Women on Antiretroviral Therapy$163,365
K23 · FY2018 · HD · contact PI
Decreasing Adverse Birth Outcomes among HIV-infected Women on Antiretroviral Therapy$163,112
K23 · FY2017 · HD · contact PI